Effettuare il login Iscriviti gratis

Adaptimmune Therapeutics Plc Capitalizzazione di mercato

Cos'è Capitalizzazione di mercato di Adaptimmune Therapeutics Plc?

Capitalizzazione di mercato di Adaptimmune Therapeutics Plc è $226.08M

Qual è la definizione di Capitalizzazione di mercato?



La capitalizzazione di mercato è il valore di mercato in un momento nel tempo delle azioni in circolazione di una società quotata in Borsa, essendo uguale al prezzo delle azioni in quel momento moltiplicato per il numero di azioni in circolazione .

As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.

Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.

The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.

Capitalizzazione di mercato di aziende nel Health Care settore su NASDAQ rispetto a Adaptimmune Therapeutics Plc

Cosa fa Adaptimmune Therapeutics Plc?

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Aziende con capitalizzazione di mercato simili a Adaptimmune Therapeutics Plc